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ABSTRACT
Cardiotocography (CTG), the continuous and simultaneous recording of the fetal 
heart rate (FHR) and the maternal contractions, is a method widely used for the 
assessment of fetal well-being, predominantly in pregnancies with increased risk of 
complications.
The Oxford system, developed by Dawes and Redman and implemented in the 
Sonicaid Fetalcare monitor, provides a computerised analysis of the CTG (cCTG) 
by taking into consideration a number of numerical, computer based parameters, 
with Short Term Variation (STV), a measure of the micro fluctuations of the FHR, 
being one of the most significant ones, especially in the monitoring of fetuses with 
Intrauterine Growth Restriction (IUGR).
The Dawes-Redman algorithm calculates the STV by dividing each minute into 
16 segments, each one being 3,75 seconds long and including 7-10 fetal 
heartbeats, or 6-9 pulse intervals (STV16). The average pulse interval in each 
section is calculated and the STV16 derives from the difference of the average 
pulse intervals between two sections. This calculated STV16 does not, however, 
equal the beat-to-beat variation of the FHR.
A series of important studies has demonstrated that, when monitoring fetuses 
with preterm IUGR, STV16 values under 3ms correlate positively with the 
development of metabolic acidemia and should prompt to delivery.
Theoretically, measurement of the pulse interval in much smaller time fractions, 
so that every heartbeat would be taken into consideration (instead of one every 
7-10 heartbeats), would lead to a more accurate approximation of the beat-to-beat 
variation with significant advantages for the antenatal monitoring of the fetus. 
The IntelliSpace Perinatal by Philips Medical, which measures the STV by 
dividing each minute into 240 segments (STV240), attempts to better approximate 
the beat-to-beat variation of the FHR. 
 2
An effort in our department to implement the existing cut-off values of the STV16 
as reference values for the new STV240 algorithm has resulted in highly abnormal 
findings, with STV240 values significantly below the cut-off values of the STV16.
This observation led to the hypothesis, that the reference values for the STV240 
should be different, and, more precisely, lower in comparison to the existing 
reference values for the STV16. This hypothesis was not only based on clinical 
observation. The discrepancy noted between the two different algorithms is also 
logically sound, as it is to be expected that the variation between two subsequent 
beats will be notably lower as the variation between 7-10 subsequent heartbeats.
We therefore conducted a single-center, non-interventional, prospective clinical 
study in order to develop clinically relevant reference values for the STV240 and to 
compare the reference values for the STV240 to the ones for the STV16. At the 
same time, we studied the effects of RDS prophylaxis on STV240 and STV16, in 
order to verify if the known transient effects of corticosteroids on the STV could also 
be detected with the new algorithm for the STV240.
A total of 228 CTG traces from 94 patients (86 singleton and 8 twin pregnancies) 
were registered and included in the final statistical analysis for the development of 
the reference values.
The values of the STV240 were significantly lower in comparison to the ones of 
the STV16. Moreover, not only the mean values but 95% of the values for the 
STV240 lay beneath the existent cut-off value for the STV16.
The STV240 has a relative strong, statistically significant correlation with the 
STV16 (r=0,646, p<0,001). A medium, although statistically significant correlation 
(r=0,373, p<0,001) between week of pregnancy and STV240 was documented, 
whereas the correlation between STV16 and week of pregnancy was negligible.
A transient increase of both the STV240 and STV16 was documented in the first 
24h after the first intramuscular corticosteroid administration, when compared to the 
STV240 and STV16 without RDS prophylaxis or at least 72h after. This was 
followed by a transient decrease of both the STV240 and STV16 between 24h and 
72h after the first intramuscular corticosteroid injection
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Our results confirmed our hypothesis and allowed us to calculate the reference 
values for the STV240. Of paramount importance for every clinician using the new 
algorithm in her or his everyday practice, is to know that the normal values for the 
STV240 (not only the mean value but also the 95th percentile) lie beneath the, up 
until now, established cut-off value for the STV16. This stresses the fact that every 
clinician using cCTG should be, in advance, well aware of the algorithm 
implemented in his cCTG monitors. Otherwise, there is the threat of unnecessary 
iatrogenic premature deliveries, with all relevant risks. 
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DEUTSCHE ZUSAMMENFASSUNG
Cardiotocographie (CTG), die kontinuierliche und gleichzeitige Aufzeichnung der 
fetalen Herzfrequenz (FHF) und der mütterlichen Kontraktionen, ist eine Methode, 
die weithin für die Beurteilung des fetalen Wohlbefindens verwendet wird, 
vorwiegend bei Schwangerschaften mit erhöhtem Komplikationsrisiko.
Das von Dawes und Redman entwickelte Oxford-System, welches im Sonicaid 
Fetalcare Monitor implementiert ist, bietet eine computerisierte Analyse des CTG 
(cCTG) unter Berücksichtigung einer Reihe von numerischen, computerbasierten 
Parametern an. Kurzzeitvariation (KZV), eine Maßnahme der Mikrofluktuationen 
des FHF, ist einer der bedeutendsten computerbasierten Parameter, vor allem bei 
der Überwachung von Feten mit intrauteriner Wachstumsrestriktion (IUGR).
Der Dawes-Redman-Algorithmus berechnet die KZV, indem er jede Minute in 16 
Segmente unterteilt, wobei jedes 3,75 Sekunden lang ist und 7-10 fetale 
Herzschläge oder 6-9 Pulsintervalle (KZV16) enthält. Das mittlere Pulsintervall in 
jedem Abschnitt wird berechnet und die KZV16 ergibt sich aus der Differenz der 
mittleren Pulsintervalle zwischen zwei Abschnitten. Diese berechnete KZV16 
entspricht jedoch nicht der beat-to-beat-Variation der FHF.
Eine Reihe wichtiger Studien hat gezeigt, dass bei der Überwachung von Feten 
mit früher IUGR KZV-Werte unter 3ms positiv mit der Entwicklung einer 
metabolischen Azidämie korrelieren und zur Entbindung führen sollten.
Theoretisch würde die Messung des Pulsintervalls in viel kleineren 
Zeitabschnitten, so dass jeder Herzschlag berücksichtigt wäre (statt eines alle 7-10 
Herzschläge), zu einer genaueren Annäherung der beat-to-beat-Variation der FHF 
führen, mit deutlichen Vorteilen für die antepartale Überwachung des Fetus.
Das IntelliSpace Perinatal von Philips Medical, das die KZV auswertet, indem es 
jede Minute in 240 Segmente teilt (KZV240), versucht die beat-to-beat Variation der 
FHF besser anzunähern.
Ein Versuch, in unserer Abteilung, die vorhandenen cut-off-Werte der KZV16 als 
Referenzwerte für den neuen KZV240-Algorithmus zu implementieren, hat zu sehr 
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auffälligen Befunden geführt, wobei die KZV240-Werte deutlich unter den cut-off-
Werten der KZV16 lagen.
Diese Beobachtung führte zu der Hypothese, dass die Referenzwerte für die 
KZV240 im Vergleich zu den vorhandenen Referenzwerten für die KZV16 niedriger 
sein sollten. Diese Hypothese beruht nicht nur auf der klinischen Beobachtung. Die 
zwischen den beiden verschiedenen Algorithmen bemerkte Diskrepanz ist auch 
theoretisch zu erwarten, weil die Variation zwischen zwei nachfolgenden 
Herzschlägen deutlich geringer als die Variation zwischen 7-10 nachfolgenden 
Herzschlägen ist.
Wir haben daher in unserer Klinik eine nicht interventionelle, prospektive 
klinische Studie durchgeführt, um klinisch relevante Referenzwerte für die KZV240 
zu entwickeln und diese mit denen für die KZV16 zu vergleichen. Gleichzeitig 
haben wir die Effekte der RDS-Prophylaxe auf KZV240 und KZV16 untersucht, um 
zu prüfen, ob die bekannten transienten Effekte von Kortikosteroiden auf der KZV 
auch mit dem neuen Algorithmus für die KZV240 nachgewiesen werden können.
Insgesamt wurden 228 CTGs von 94 Patientinnen (86 Einlings- und 8 Zwillings-
Schwangerschaften) registriert und in die endgültige statistische Analyse zur 
Entwicklung der Referenzwerte einbezogen.
Die Werte der KZV240 waren im Vergleich zu der KZV16 deutlich niedriger. 
Darüber hinaus lagen nicht nur die Mittelwerte, sondern 95% der Werte für die 
KZV240 unter dem vorhandenen cut-off-Wert für die KZV16.
Die KZV240 hat eine relativ starke, statistisch signifikante Korrelation mit der 
KZV16 (r = 0,646, p <0,001). Eine mittlere, obwohl statistisch signifikante 
Korrelation (r = 0,373, p <0,001) zwischen Schwangerschaftswoche (SSW) und 
KZV240 wurde dokumentiert, während die Korrelation zwischen KZV16 und SSW 
vernachlässig war.
In den ersten 24h nach der ersten intramuskulären Kortikosteroidgabe wurde 
eine vorübergehende Zunahme sowohl der KZV240 als auch der KZV16 
dokumentiert, im Vergleich zu den KZV240 und KZV16 ohne RDS-Prophylaxe oder 
mindestens 72h danach. Darauf folgte eine vorübergehende Abnahme sowohl der 
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KZV240 als auch der KZV16 zwischen 24h und 72h nach der ersten 
intramuskulären Kortikosteroidgabe.
Unsere Ergebnisse bestätigten unsere Hypothese und erlaubten uns, die 
Referenzwerte für die KZV240 zu berechnen. Es ist extrem wichtig für jeden Arzt, 
der den neuen Algorithmus in seiner alltäglichen Praxis verwendet, zu wissen, dass 
die Normalwerte für die KZV240 (nicht nur der Mittelwert, sondern auch die 95. 
Perzentile) unterhalb der bislang etablierten cut-off-Werte für die KZV16 liegen. 
Dies unterstreicht die Tatsache, dass bei der Interpretation der KZV des cCTGs der 
verwendete Algorithmus berücksichtigt werden sollte. Ansonsten besteht die Gefahr 





Timely recognition and appropriate management of high risk pregnancies are of 
paramount importance for every obstetrician. Small for gestational age (SGA) 
fetuses constitute a major part of pregnancies at increased risk for poor perinatal 
outcome. However, from the pool of the SGA fetuses, the ones with normal 
placental function are not at risk for adverse perinatal events [Soothill et al, 1999]. 
These constitutionally small fetuses must be differentiated from the ones with 
Intrauterine Growth Restriction (IUGR). 
IUGR is characterised by placental dysfunction and carries an increased risk of 
perinatal mortality and morbidity [Illanes and Soothill, 2004]. IUGR is shown to be 
associated with stillbirth [Cnattingius et al, 1998], birth hypoxia [McIntire, 1999], 
increased prevalence of neonatal complications [Bernstein et al, 2000], impaired 
neurodevelopment [Kok et al 1998; Roth et al, 1999], adult hypertension [Lackland, 
2003] and type II diabetes mellitus [Hales and Ozanne, 2003].
The initial screening method for the early recognition of IUGR fetuses is based 
on a combination of biometric parameters with fetal Doppler values. Sonographic 
fetometry is used to identify SGA fetuses and fetal Doppler flow velocimetry is in 
turn used as a direct indicator of placental dysfunction, in order to recognise the 
IUGR fetuses [Baschat et al, 2001]. Progressively abnormal pulsatile index in the 
umbilical and / or middle cerebral artery is a sign of placental insufficiency with 
increasing hypoxemia and/or hypoxia, whereas an abnormal Ductus venosus 
waveform usually correlates with acute changes present in advanced stages of fetal 
compromise [Figueras and Gardosi, 2011]. 
Once the diagnosis of IUGR has been made, the focus is shifted to the 
appropriate monitoring and accordingly timing of delivery. In cases of late IUGR, 
where the risk of prolongation of pregnancy overcomes the benefits, timing of 
delivery is a relatively simple decision. However, in cases of early IUGR, this 
decision can become a very difficult task, in trying to balance the risk between 
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potential iatrogenic prematurity and prolongation of the exposure to an adverse 
intrauterine milieu.
At this point, cardiotocography (CTG) has been employed as a pivotal tool in the 
day-to-day monitoring of the antenatal well-being of the IUGR fetus [Visser and 
Huisjes, 1977]. Since the first introduction of CTG in the antenatal surveillance of 
high risk pregnancies, there has been great progress in the recording of the fetal 
heart rate (FHR) as well as its interpretation. The advances in the area of 
Information & Communication Technology has allowed for the evolution of the 
traditional CTG to the nowadays widely spreading implementation of computerised 
CTG (cCTG) in the clinical practice.  
Cardiotocography
Cardiotocography is the continuous and simultaneous recording of the fetal heart 
rate (FHR) and the maternal contractions (Figure 1). CTG is a method widely used 
for the assessment of fetal well-being, predominantly in pregnancies with increased 
risk of complications, such as IUGR [Grivell et al, 2015]. 
Since 1766, when the auscultation of the FHR was reported for the first time by 
Wrisberg [Roederer, 1766], various technological advancements have allowed for 
the monitoring of the fetal heart rate and of the uterine contractions to become what 
is nowadays widely known and used as CTG. 
The development of CTG is attributed mainly to three researchers: Caldeyro-
Barcia, Hon and Hammacher. 
Caldeyro-Barcia studied in the early 50s’ the physiology of the uterine 
contractions, through the insertion of a catheter in the amniotic cavity [Caldeyro-
Barcia et al, 1959; Alvarez and Caldeyro-Barcia, 1954]. At about the same time, 
Hon introduced the monitoring of the fetal heart rate using an electrode inserted 
through the vagina and attached to the fetal scalp [Hon, 1958; Hon, 1966].
The great breakthrough occurred in the mid-60s’, when Hammacher, in 
cooperation with Hewlett-Packard, achieved to document the fetal heart rate via 
external phonocardiotocography. Calculation of the fetal heart rate was made 
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possible through measurement of the fetal pulse interval [Hammacher, 1962; 
Hammacher 1967; Hammacher, 1969]. 
Figure 1: example of a normal CTG trace
The evolution of the Doppler technology enabled great progress in the monitoring 
of the fetal heart rate. In the 70s’, the use of a wide-angled ultrasound transducer 
on the abdominal wall of the mother for the monitoring of the FHR found 
widespread use [Hop and Heinrich, 1979]. 
Those developments led to what is nowadays known as CTG, the continuous 
recording of the FHR and of the uterine activity. The fetal heart rate is obtained via 
an ultrasound transducer placed on the mother’s abdomen and the uterine activity 
is registered via a second transducer placed also on the mother’s abdomen, over 
the uterine fundus (Figure 2). Both traces are documented simultaneously onto a 
paper strip [Alfirevic et al, 2013].
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Figure 2: Ultrasound transducer for the FHR and tocometer
The components of the fetal heart rate that are routinely assessed are baseline 
rate, baseline variability, accelerations and decelerations. There are various criteria 
for the interpretation of the CTG. Widely used among those are the Fischer-Score 
(Table 1) [Fischer et al, 1976] and the FIGO-Score (Table 2) [Ayres-de-Campos et 
al, 2015]. All these score-systems use the optical, subjective evaluation of the 
above mentioned components of the fetal heart rate as an indicator of fetal well-
being. 
The established normal values for the above named parameters are [RCOG, 
2001]:
- oscillation amplitude of the FHR more than 5 bpm
- baseline of the FHR between 110 and 160 bpm (beats per minute)
- presence of at least two accelerations of the FHR in 20 minutes
- absence of decelerations. 
The use of the above parameters derives from the physiology of the fetal cardiac 
function and the regulation of the FHR from the fetal autonomous nervous system 
[Kamath and Fallen, 1993]. As the physiological mechanisms that regulate the FHR 
depend on an intact central nervous system, the failure of the fetus to demonstrate 
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a normal pattern of FHR may be the result of grave hypoxic brain damage [ACOG, 
2000].
Table 1: Fischer-Score for the antepartum visual interpretation of the CTG
Table 2: FIGO-Score for the intrapartum visual interpretation of the CTG
CTG is a very sensitive screening test, with a high negative predictive value, 
lacks however on specificity and positive predictive value. A normal, reactive CTG 
trace is reassuring, as it reflects a normal, uncompromised fetus. On the other 
hand, an abnormal CTG trace can reflect a range of fetal conditions, not all of which 
are necessarily the result of fetal hypoxemia or metabolical acidosis [Spencer, 
1993]. 
0 points 1 point 2 points
Baseline <100 or >180 bpm 100-110 or 160-180 bpm 110-160 bpm
Bandwidth <5 5-10 or >30 10-30
Zero-crossings <2 2-6 >6
Accelerations none periodic sporadic
Decelerations late early none, variable
8-10 points physiologic fetal condition
5-7 points questionable fetal condition
0-4 points critical fetal condition
Normal Suspicious Pathological
Baseline 110-160 bpm
Lacking at least one 
characteristic of 





Reduced variability for > 50 min, 
increased variability for >30 min, 




Repetitive late or prolonged 
decelerations during > 30 min or 
20 min if reduced variability




low probability of fetal 
hypoxia/acidosis 
high probability of fetal 
hypoxia/acidosis 
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A major restriction of CTG is the intra-observer variability of its subjective visual 
assessment and the lack of reproducibility of its results [Bernardes et al, 1997; 
Devane and Lalor, 2005]. The interpretation of the CTG is highly dependent on the 
level of expertise of the clinician and even experts don’t always come in agreement 
when evaluating series of CTGs [Hruban et al, 2015]. And while the level of 
agreement is high when it comes to normal CTG traces, it drastically drops with 
suspect or pathological findings, when further intervention is needed [Ayres-de-
Campos et al, 1999]. It is furthermore very intriguing, that a physician’s 
interpretation of a CTG-trace and thus hers / his further recommendations vary 
significantly, depending on hers / his knowledge of fetal outcome [Reif et al, 2016].
Remarkably, despite traditional CTG being routinely used in the antenatal 
monitoring of high-risk pregnancies, such as pregnancies complicated with IUGR, 
there isn’t enough evidence to support its effectiveness in improving the perinatal 
outcome [Brown et al, 1982; Kidd et al, 1985; Grivell et al, 2015], although there is 
a documented association between abnormal CTG traces and poor perinatal 
outcome [Lumley et al, 1983]. On the other hand, antenatal CTG monitoring has 
been shown to reduce inpatient management of high-risk pregnancies, when a 
reassuring trace was obtained [Flynn et al 1982]. 
In order to overcome these shortcomings of traditional antenatal CTG monitoring, 
the need for an advanced, electronic and objective assessment of the fetal heart 
rate has led to the development of cCTG.
Computerised cardiotocography
In an effort to objectify the interpretation and evaluation of CTG, Dawes and 
Redman introduced in the 1980s the computerised analysis of the CTG [Dawes et 
al, 1991; Dawes et al, 1991]. They developed a system, also known as Oxford 
system, which is implemented in the Sonicaid Fetalcare monitor and takes into 
consideration a number of numerical, computer based, parameters known as 
Dawes-Redman criteria (Table 3) [Pardey et al 2002]. Those criteria can be broadly 
summarised as:
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- STV of 3ms or greater
- No evidence of a sinusoidal rhythm 
- At least one episode of high variation
- No large or repeated decelerations
- Accelerations and / or fetal movements
- No evidence of a baseline misfit
- A normal basal heart rate.
Table 3: Oxford system’s criteria for normality
If all of the above mentioned criteria are met after the first 10 minutes of the 
recording, the system will report “Criteria Met” and the monitoring can be stopped, 
as the trace can be interpreted as reassuring. If after 10 minutes the criteria are not 
met, then the monitoring should continue and the trace will be reevaluated every 20 
minutes and will eventually stop to report “Criteria Met” or go on for 60 minutes if 
the criteria are not met. If the criteria are never met in the period of 60 minutes, 
then the monitoring will stop with the report “Criteria Not Met”, in which case the 
trace is non-reassuring and further clinical evaluation and eventually action is 
At least one episode of high variation during the recording
STV >3ms (but average LTV of all episodes of high variation >3rd percentile for the gestational age when 
STV 3-4,5ms)
No evidence of high-frequency sinusoidal rhythm
At least one acceleration or fetal movement rate >20/h and average LTV of all episodes of high variation 
>10th percentile for the gestational age
At least one fetal movement or three accelerations
No deceleration of >20 lost beats if recording <30min, no more than one deceleration of 21-100 lost beats 
if recording >30min, no decelerations at all of >100 lost beats
Basal heart rate 116-160 bpm if recording <30min
LTV within 3 SDs of its estimated value or STV>5ms and one episode of high variation with >0,5 fetal 
movements/min and basal heart rate ≥120 bpm and signal loss <30%
Final epoch of the recording not part of a deceleration if recording <60min or deceleration not >20 lost 
beats if recording 60min
No suspected artefacts at the end of the recording if recording <60min
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needed [Dawes et al, 1991]. It is of paramount importance to await the full 60 
minutes before interpreting a trace as non-reassuring, as a fetal sleep circle can 
last up to 50 minutes, in which period there is no reactive fetal heart pattern [Dawes 
et al, 1996]. It has been demonstrated, that many of the above named parameters 
have a direct, independent correlation to the fetal outcome [Galazios et al, 2010].
The development of cCTG offered many advantages in comparison to traditional 
CTG. First of all it made possible to eliminate the intra-observer variability and 
improve the reproducibility of the results, as the interpretation of the CTG trace is 
performed by a computer program [Chen et al, 2014]. Another important 
advancement was the reducing of the recording time. As mentioned above, a CTG 
trace can often be evaluated as reassuring in only 10 minutes, whereas a traditional 
CTG needs to be at least 20 to 30 minutes long in order to be evaluable. Last but 
not least, the cCTG technology allowed for the determination of FHR parameters 
such as long- and short-term variation (LTV and STV) that cannot otherwise be 
assessed visually [Dawes et al, 1991].
The effectiveness of cCTG in comparison to traditional CTG has been mainly 
studied in high risk pregnancies, such as pregnancies complicated by IUGR, 
hypertension, preeclampsia, diabetes, etc. There are two major studies, which 
evaluated the effects of cCTG in comparison to traditional CTG in terms of perinatal 
outcome, caesarean section rates, number of diagnostic interventions and time 
spent in antenatal monitoring [Bracero et al, 1999; Steyn and Odenaal, 1997]. Both 
studies showed an improvement of perinatal outcome, although the caesarean 
section rates did not differ between the two groups. Furthermore, a reduction in the 
number of diagnostic interventions as well as time spent in antenatal monitoring 
was confirmed in the group of cCTG.
All of the above advantages of cCTG have led to its more and more widespread 
implementation in the clinical praxis. However, there is still a long way to go, before 
cCTG replaces traditional CTG as part of the routine antenatal monitoring in every 
clinic and every hospital. For the time being, cCTG is mainly implemented in major 
perinatal centres and university hospitals, which manage a large number of high 
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risk pregnancies, as part of the routine antenatal monitoring of these high risk 
cases.
Short term variation of the fetal heart rate
One of the parameters of the Dawes-Redman criteria is the Short Term Variation 
(STV) of the FHR. STV is one of the most significant parameters, especially in the 
antenatal monitoring of IUGR fetuses [Snijders et al, 1992].
STV is a measure of the micro fluctuations of the FHR. In the Dawes-Redman 
system, STV is calculated by dividing each minute into 16 segments, each one 
being 3,75 seconds long and including 7-10 fetal heartbeats, or 6-9 pulse intervals. 
The average pulse interval in each section is calculated and the STV derives from 
the difference of the average pulse intervals between two sections. For that reason 
the STV is calculated in milliseconds (ms) [Sonicaid Fetalcare Clinical Application 
Guide]. This calculated STV does not however equal the beat-to-beat variation of 
the FHR, which cannot be measured with external Doppler ultrasound technology. 
The STV is independent from the baseline of the FHR. Two major factors that 
can influence the STV are the sleep circle of the fetus and the administration of 
corticosteroids to induce lung maturation. 
It is normal for a fetus to have a long quiet period as in deep sleep, where the 
FHR is relatively flat with low STV. As such normal episodes of deep sleep can last 
up to 40 or 50 minutes, it is important to wait for at least 60 minutes before a trace 
with a low STV is characterised as abnormal [Dawes et al, 1996]. 
Furthermore, the administration of corticosteroids in the context of respiratory 
distress syndrome (RDS) prophylaxis in cases of threatened premature delivery, 
has a similar impact on the STV, as it can lead to transiently reduced STV. For that 
reason it is important to disregard the possible STV alterations that occur during the 
first 3 days after the administration of the RDS prophylaxis [Rotmensch et al, 2005].
It has already been shown, early on that in cases of non-reactive fetal trace 
(without episodes of high variation) low STV is strongly linked to developing 
metabolic acidaemia and impending intrauterine death [Street et al, 1991]. A low 
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STV is usually seen in chronically stressed IUGR fetuses. A series of important 
studies has demonstrated, that, when monitoring fetuses with preterm IUGR, STV 
changes can and should play an important role on the timing of delivery.
The first major study on the role of STV in the monitoring of IUGR fetuses was 
conducted by Street et al in 1991, as until that time the role of LTV was more 
prominently studied.  This study group was able to demonstrate, that the STV has a 
positive correlation to the LTV, although STV can better recognise metabolic 
acidemia, by STV values under 3 ms. Furthermore, all terminal cases can be 
identified, when the STV drops under 2,5 ms [Street et al, 1991].
The study group of Dawes et al followed one year later to demonstrate, that by 
STV values under 2,6 ms, 35% of all monitored fetuses will have a metabolic 
academia on point of birth, or will even have suffered intrauterine demise [Dawes et 
al, 1992].
Guzman et al confirmed in 1996, that low STV in IUGR fetuses has a significant 
correlation to umbilical artery pH after birth and could consistently predict academia 
at birth. This study group set however the cut-off value of the STV higher, at 3,5 ms 
[Guzman et al, 1996].
In 2001 Hecher et al demonstrated that the STV together with the pulsatility index 
of the ductus venosus (DVPI) are the most important markers of impending fetal 
acidosis and should play a paramount role on the timing of the delivery of IUGR 
fetuses. They used in their study a cut-off value of 3 ms [Hecher et al, 2001].
In 2004 Anceschi et al set an even higher cut-off for the STV by 4,5 ms. They 
suggested that STV values under this cut-off can predict a developing metabolic 
acidaemia with 100% sensitivity and 70% specificity [Anceschi et al, 2004].
Serra et al in 2008 confirmed for one more time the pivotal role of the STV as an 
important predictor of the perinatal outcome of IUGR fetuses. The cut-off value was 
set again by 3 ms [Serra et al, 2008].
The latest development in the role of STV in the monitoring of IUGR fetuses took 
place in 2015, with the final disclosure of the results of the TRUFFLE study. 
According to the results of this study, even when the primary monitoring of IUGR 
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fetuses and decision making regarding the timing of delivery is based on other 
parameters, such as fetal Doppler values, the STV should always be taken into 
consideration and even be used as a safety net. Delivery shouldn’t be delayed after 
the STV has reached a critical low (2,6 ms for 26.0 to 28.9 weeks of gestation and 
3 ms for 29.0 to 32.0 weeks of gestation), even when the other monitored 
parameters are still normal [Lees et al, 2015].
To add to the TRUFFLE-Study, a secondary analysis of its results by Wolf et al. in 
2016, demonstrated that it is essential to monitor the STV of IUGR fetuses even 
more than once daily. Furthermore, they confirmed that it is safe to wait for a low 
STV, as long as the DVPI remains normal [Wolf et al, 2016].
Challenges in the interpretation of computerised CTG
Since Cardiotocography was first developed and used in clinical practice until the 
present day, many and major advancements took place that helped evolve CTG 
into the indispensable diagnostic and monitoring tool that it constitutes nowadays. 
A pivotal step in this way was the introduction of cCTG in the 1980s, which 
opened new horizons to the objective and reproducible monitoring, especially of 
high risk pregnancies, such as pregnancies complicated with IUGR.
After the TRUFFLE-Study, the pivotal role of cCTG, and especially of the STV, 
has been brought in the spotlight in the management of IUGR. 
Every physician is put before an extremely difficult and at the same time of 
paramount importance decision, when it comes to the timing of the delivery of a 
premature fetus with IUGR. In this direction, every tool that can aid with this 
decision in an objective and reproducible manner is invaluable. 
It appears that the STV of the FHR can play, at least part of, this role. The 
available studies up until now support this fact. However, most of the later, including 
the multicenter TRUFFLE-Study, limit their results between the 26th and 32nd week 
of gestation. Thus, it is crucial that research in this field does not cease, that the 
studied spectrum becomes wider and that further emerging technological 
developments be constantly implemented into the existing methods.
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Potential restrictions of the currently available methods for the antepartum 
monitoring of IUGR, and especially early-IUGR, fetuses should be recognised. For 
instance, all of the above mentioned studies draw their results based on the 
Dawes-Redman algorithm, which is however only implemented in the Sonicaid 
Fetalcare monitor. It remains unclear, if the same rules and normal values apply to 
parameters such as the STV, calculated using other commercially available 
monitoring systems. Until this grey zone is clarified through more studies, it is 
important for every physician to know, that only parameters that are calculated with 
the Dawes-Redman system can be compared to the ones described in the current 
literature [Kouskouti et al, 2017].
It is therefore essential, that effort should be put in the evolution of the already 
existing methods or even the development of new, more refined ones.
RESEARCH QUESTION
Cardiotocography (CTG) constitutes a pivotal element in the monitoring of the 
antenatal wellbeing of the fetus [Grivell et al, 2015]. Traditionally, visual analysis 
and subjective interpretation of the CTG-tracings have been used to guide clinical 
decisions, such as time point and mode of delivery. Visual analysis based on 
relevant score systems (e.g. FIGO, FISHER) is very effective in detecting a 
“terminal trace” when the fetal heart rate (FHR) is flat with repetitive shallow 
decelerations [Visser and Huisjes, 1977]. However, this is a rare and extreme 
situation and the fetuses that manifest this kind of trace are already severely 
affected. More commonly the trace abnormalities are subtle, which makes the 
visual interpretation difficult and often inaccurate [Bernardes et al, 1997].
Computerised analysis of the fetal heart rate (FHR), introduced more than two 
decades ago, has conferred important advantages in the evaluation of the fetal 
status antenatally [Dawes et al, 1991]. The numerical measures of the FHR pattern 
derived from the computerised analysis have been shown to correlate with other 
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objective parameters of fetal health. Quantitative results, presented in a consistent 
manner, allow for improved accuracy and more efficient process of information and, 
therefore, shorter recording time [Dawes et al, 1991]. 
Currently, one of the most widespread systems for cCTG analysis is the Dawes-
Redman system (Sonicaid Fetalcare by Huntleigh Healthcare). This system takes 
into consideration a number of numerical, computer based, parameters known as 
Dawes-Redman criteria [Pardey et al, 2002], with Short Term Variation (STV) of the 
FHR being one of the most significant, especially in the antenatal monitoring of 
fetuses with intrauterine growth restriction (IUGR) [Dawes et al, 1990; Snijders et 
al, 1992].
IUGR is one of the most significant diagnosis that an obstetrician needs to be 
able to make and consequently monitor throughout a pregnancy.  From the major 
pool of small for gestational age (SGA) fetuses, the ones with IUGR are 
characterised by placental dysfunction and carry an increased risk of perinatal 
mortality and morbidity. IUGR has been associated with stillbirth, birth hypoxia, 
increased prevalence of neonatal complications, impaired neurodevelopment, adult 
hypertension and type II diabetes mellitus [Illanes and Soothill, 2004].
The diagnosis of IUGR is based on a combination of abnormal biometric 
parameters with abnormal fetal Doppler values. A direct indicator of placental 
dysfunction, which serves for the initial diagnosis and the subsequent monitoring in 
cases of IUGR, is the fetal Doppler flow velocimetry in certain vessels, according to 
fetal state, which measures the regional blood flow changes that occur in case of 
fetal hypoxemia [Baschat et al, 2001]. Once the diagnosis of IUGR has been 
established, CTG, and especially the STV of the FHR as part of the cCTG, plays, 
along with Doppler sonography, a major role in the subsequent monitoring and 
timing of delivery of IUGR fetuses [Snijders et al, 1992].
STV is a measure of the microfluctuations of the FHR. It is independent of the 
fetal baseline and, in cases of non-reactive fetal trace (without episodes of high 
variation), low STV is strongly linked to developing metabolic acidemia and 
impending intrauterine death [Street et al, 1991]. A low STV is usually seen in 
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chronically stressed IUGR fetuses [Dawes et al, 1992; Guzman et al, 1996]. 
However, a trace with low STV may also correspond to a fetus having a long quiet 
period, as in deep sleep, where the FHR is relatively flat with low STV. As such 
episodes of deep sleep can last up to 40 or 50 minutes, it is important to wait for at 
least 1 hour before such a trace with a low STV is characterised as abnormal 
[Dawes et al, 1996]. Furthermore, the administration of corticosteroids in cases of 
respiratory distress syndrome (RDS) prophylaxis has a similar impact on the STV, 
as it leads to transiently increased STV within the first 24h followed by transiently 
reduced STV until the first 72h. For that reason, the STV alterations registered 
during the time of RDS prophylaxis should not be taken into consideration for the 
clinical decision making [Mulder et al, 1994; Rotmensch et al, 2005]. 
It has been shown that STV changes can and should play an important role in 
the timing of delivery of fetuses with preterm IUGR, even when the primary 
monitoring and decision making is based on other parameters, such as fetal 
Doppler values [Hecher et al, 2001]. In cases of IUGR fetuses, delivery shouldn’t be 
delayed after the STV has reached a critically low value, even when the other 
monitored parameters are still normal [Anceschi et al, 2004; Serraet al, 2008; Lees 
et al, 2015].
In the Dawes-Redman system, the STV is measured by dividing each minute into 
16 segments, each one being 3,75 seconds long and including 7-10 fetal 
heartbeats or 6-9 pulse intervals (STV16). The average pulse interval in each 
segment is calculated and the difference of those pulse intervals between two 
segments determines the STV [Sonicaid Fetalcare Clinical Application Guide]. From 
the above, it is clear that the STV16 does not equal the beat-to-beat variation of the 
FHR.
Theoretically, measurement of the pulse interval in much smaller time fractions, 
so that every heartbeat would be taken into consideration (instead of one every 
7-10 heartbeats), would lead to a more accurate approximation of the beat to beat 
variation with significant advantages for the antenatal monitoring of the fetus. 
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New developments in Information and Communication Technology (ICT) have led 
to the development of new algorithms, which take into consideration every single 
heartbeat for the calculation of the STV [Amorim-Costa et al, 2016]. One of them is 
the IntelliSpace Perinatal by Philips Medical, which measures the STV by dividing 
each minute into 240 segments (STV240), thus attempting to better approximate 
the beat-to-beat variation of the FHR. The pulse interval in each section is then 
calculated (with redundant values coming from the same pulse being automatically 
disregarded) and the difference of those pulse intervals determines the STV240. 
One of the problems that arise after the development of a new computing 
algorithm for the calculation of any clinical parameter is the lack of reference 
values, based on a clinical database. Without reference values for the specific 
algorithm, no clinical consequences can be drawn [Siest et al, 2013]. It has already 
been shown, that, when calculated with the use of different algorithms, the normal 
values for the STV differ to the ones known for the Dawes-Redman system 
[Amorim-Costa et al, 2016].
An effort in our department to implement the existing cut-off values of the STV16 
as reference values for the new STV240 algorithm has resulted in highly abnormal 
findings, with STV240-values significantly below the cut-off values of the STV16 
[Serra et al, 2009]. This event was not only noted in IUGR cases, but also in 
healthy, appropriate for gestational age (AGA) fetuses. Therefore, despite their 
accuracy, the values derived from the new algorithm cannot contribute to the 
decision making process, as they cannot be readily categorised as normal or 
abnormal.
This observation led to the formation of the hypothesis, that the reference values 
for the STV240 should be different, and, more precisely, lower in comparison to the 
existing reference values for the STV16. This hypothesis is not only based on 
clinical observation. The discrepancy noted between the two different algorithms is 
also logically sound, as it is to be expected that the variation between two 
subsequent beats will be notably lower as the variation between 7-10 subsequent 
heartbeats.
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As the new algorithm is being implemented in the clinical practice it is important 
to have reference values. Therefore, we conducted an observational, prospective 
clinical study in order to develop clinically relevant reference values for the STV240 
and compare the reference values for the STV240 to the ones for the STV16.
At the same time, we studied the effects of RDS prophylaxis on STV240 and 
STV16 in order to verify if the known transient effects of corticosteroids on the STV 
could also be detected with the new algorithm for the STV240.
 Our results will hopefully allow for more accurate interpretation of the 
computerised CTG findings and better clinical monitoring of IUGR fetuses.
METHODS
Study design
This was a single-center, non-interventional study. The acquisition of the data 
followed in a prospective manner. The CTG traces that were acquired as part of the 
routine antenatal monitoring of our pregnant patients, were gathered and 
subsequently analysed with both algorithms (STV240 and STV16).
Study population
The CTG traces were collected from September 2015 until October 2016 in the 
antenatal department of the Klinik Hallerwiese, Nuremberg, Germany. The study 
included CTG traces starting from 24.0 until 33.6 weeks of gestation. 
Only CTG traces of appropriate for gestational age (AGA) fetuses with normal 
fetal and maternal Doppler parameters (umbilical artery (UA), middle cerebral artery 
(MCA), uterine artery (UtA)) were included in our study. In order to assure the 
fulfilment of this prerequisite, every patient was subjected to a thorough ultrasound 
examination with admission to the study. This included: fetal biometry 
(measurement of the head circumference, abdomen circumference, femur length) 
and Doppler flow velocimetry of the UA, MCA and UtA (Figure 3). 
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Figure 3: Ultrasound pictures of fetal biometry: a) head circumference, b) abdomen circumference, 
c) femur length and Doppler flow velocimetry: c) umbilical artery, d) middle cerebral artery e) 
uterine artery of Patients enrolled in the study
 
Pregnancies complicated with Diabetes mellitus, hypertensive disease of 
pregnancy or IUGR were excluded from our normal collective.
In cases where RDS prophylaxis was required, the CTG traces were gathered at 
a) 0-24h, b) 25-72h and c) at least 72h after the first intramuscular corticosteroid 
administration. As it is well-known and documented that corticosteroid 
administration leads to transiently altered STV (Rotmensch, 2005), only the CTG 
traces gathered at least 72h after the first intramuscular corticosteroid 
administration were used for the development of the normal ranges. The rest was 
used for the comparison of the STV under and without the influence of RDS 
prophylaxis.
Data gathering and FHR analysis
All antenatal patients who receive inpatient care at our department are routinely 
subjected to at least 2 CTGs per day. From every patient included in the study were 
recorded: 1. one CTG daily for the first 72h (0-24h, 25-48h and 49-72h) after the 
first intramuscular corticosteroid administration (in cases where RDS prophylaxis 
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was indicated) and 2. from that point on, or from the beginning in cases where no 
RDS prophylaxis was administered, one CTG trace per week of gestation, for as 
long as they were monitored in our antenatal department. 
In order to be able to calculate a satisfactory 95% confidence interval for the 
development of the normal ranges, a minimum of 20 CTG traces without the 
influence of RDS per week of pregnancy were required.
Figure 4: Avalon Fetal Monitor
All CTG traces were analysed with both the STV240 and the STV16 algorithm in 
order to acquire comparative data. Data gathering took place at the bedside as part 
of the standard antenatal CTG recording which is indicated for all pregnant patients 
who present at our clinic. The CTG devices used for the acquisition of the traces 
are the Avalon Fetal Monitors of Philips (Figure 4). These are the devices which are 
used in our everyday clinical practice for the antenatal CTG-monitoring. The Avalon 
Fetal Monitors are CE marked (Appendix A). The CTG traces were subsequently 
anonymised and submitted for analysis with both the STV240 algorithm and the 
STV16 algorithm. In this secondhand, off-line analysis, we received support from 
Philips Medizin Systeme Böblingen: the anonymised data were submitted to the 
R&D Department of Philips, which subsequently analysed these traces with both 
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algorithms and provided us with the resulting STV values. Although the Avalon Fetal 
Monitors used in our antenatal department can calculate the STV240 in real time at 
the bedside (Figure 5), we opted for the retrospective analysis, in order to make 
sure that the STV16 and STV240 resulted from the exact same part of every CTG 
trace. Each CTG trace was recorded over 60 min, as this is the necessary time in 
order to assess fetal well-being [14].
      Figure 5: example of a computerised CTG report (non-stress test)
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Data processing
The Philips Avalon Fetal Monitors EM20/30 and FM40/50 utilise a proprietary 
digital communication protocol. The Protocol is used for communication of the 
monitor base unit with the connected transducers. This closed bus-based 
communication system supports up to four transducers with real-time data 
transmission. Each transducer individually performs the signal processing and 
calculation of one or more parameter values related to the functionality of 
transducer. The ultrasound Doppler transducer, for instance, calculates the FHR 
and the fetal movement (FM) based on the received Doppler shifted signal. The 
update of the FHR values is done in fixed cycles every 16ms, independently of the 
availability of a new value. This means that a connected transducer is prompted 
every 16ms to place a data package on the bus. All data packages traveling on the 
bus are visible and accessible on the bus connectors either for other transducers or 
for a recording device. The recording device is so to say a special transducer 
listening to the messages of the other connected transducers. The messages 
passing between the transducers and the base unit are recorded in a storage 
device, together with an automatically added date and time annotation. The storage 
device basically is an exchangeable microSD card with a capacity of up to 2GB. In 
order to avoid accidental data loss, the data size of the record files is limited in size 
adjustable portions. Typically a file with the size of 5MB is able to store recordings 
of 5 minutes. With this file size setting, a session of 60 minutes creates 
approximately 12 Files. For later session recovery, the file names are automatically 
controlled depending on a power cycle of the monitor. All files in a directory having 
an identical pre-fix are considered to be a segment of a session. The SD card has 
to be replaced by an empty one on a regular basis. Typically the card can hold 1.5 
days of continuous recordings. During normal operation of use, this translates to a 
weekly exchange frequency. After downloading the SD card contents to a PC, 
further processing can take place. A MatLab program is used to separate all files 
belonging to a session. The files are subsequently processed to extract raw waves 
and parameter values. The raw waves are stored in Microsoft wave format and 
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have no meaning in this context.  The parameter values belonging to a session are 
combined and stored in file format with the extension *.cts. This file format is 
required by the IntelliSpace Perinatal program for calculation of the STV16 and 
STV240 values. The *.cts file is ASCII readable and has a structure as shown in 
Figure 6.
 
Figure 6: example of *.cts file
The file contains 7 parameter columns (FHR1 …. FMP).  If a parameter is 
available, the related column is filled with values. Exactly 4 values are necessary 
for every second. The resolution of the heart rate values is ¼ bpm. The columns on 
the left of the TOCO column have no relevance. A visualisation tool allows the 
Trace reconstruction with different speed and paper settings for quality check 
purposes and gap calculation. Figure 7 shows a reconstructed beginning of a 
session with trace gap calculation (yellowish box on the upper left side).
 
Figure 7: example of a reconstructed trace
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As shown in the picture, finding the optimum placement position of an ultrasound 
transducer is a more or less time-consuming procedure. Heart rate values recorded 
during this time are either not available or unreliable. The time for finding a stable 
position can range from a few seconds to a few minutes and can, therefore, 
influence the values of the gap calculation significantly. The unwanted idle time at 
the beginning and at the end was manually eliminated by deleting the related rows 
in the *.cts file. Files with truncated beginning and ending are marked for 
identification. The *.cts file is the input file for the offline calculation of the STV16 
and STV240 values and the gap analysis.
Statistical analysis
The statistical analysis of our data was carried out with "R: A Language and 
Environment for Statistical Computing, R Foundation for Statistical Computing, 
Vienna, Austria, 2015” (https://www.R-project.org/).
Descriptive statistics (arithmetic means, standard deviation, minimum and 
maximum, as well as the standard error of the average value) were used to depict 
the distribution of the STV240 and STV16 pro week of pregnancy. The 95%-
confidence interval was calculated from the arithmetic means and the standard 
error of the average value. 
We then performed a Pearson Correlation Coefficient “r” between STV240, 
STV16 and week of pregnancy.
The correlations between time from RDS prophylaxis and STV240 or STV16 
were examined using Kruskal Wallis ANOVA test. All tests with a two-sided p-value 
<0.05 were considered statistically significant.
Ethical aspects
The study was conducted in compliance with the protocol and the principles of 
Good Clinical Practice as described in the declaration of Helsinki. The study 
protocol was submitted to and accepted by the Ethic Committee of the Ludwig-
Maximillans-University in Munich (Nr. 391-15).
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It was an observational study with neither risks nor benefits for the participants. 
The examinations required for the study purposes were carried out as part of the 
routine antenatal monitoring that every pregnant patient receives at our department. 
All patients participating in the study had to sign an informed consent (Appendix B) 
form before their data could be used for the purposes of the study.
Data protection was of paramount importance and was respected at the outmost, 
as all data were anonymised before they left our clinic for further analysis through 
the ICT department of Philips Medical. 
RESULTS
A total of 101 patients between 24.0 and 33.6 week of pregnancy with informed 
consent were included in the study (93 singleton and 8 twin pregnancies). None of 
the patients had any of the exclusion criteria (Diabetes mellitus, hypertensive 
disease of pregnancy or IUGR). All of the fetuses were AGA with normal fetal and 
maternal Doppler parameters (umbilical artery (UA), middle cerebral artery (MCA), 
uterine artery (UtA)). This was confirmed by at least one ultrasound examination at 
admission in the study.
Table 4: Number of CTG traces included for the development of the normal ranges per week of 
pregnancy














A total of 228 CTG traces from 94 patients (86 singleton and 8 twin pregnancies) 
were registered and included in the final statistical analysis for the development of 
the reference values. A minimum of 20 CTG traces were registered per week of 
pregnancy (Table 4).
The 95% confidence interval was calculated for both the STV240 and the STV16. 
Table 5 and 6 present in detail the mean values per week of pregnancy for the 
STV240 and STV16 respectively, as well as the 95% confidence interval for both 
algorithms. 
Figure 8: Distribution curves for the STV240 and STV16 in ms irrespective of week of pregnancy
The values of the STV240 were significantly lower in comparison to the ones of 
the STV16. Moreover, not only the mean values but 95% of the values for the 
STV240 lay beneath the existent cut-off value for the STV16 (2,6ms for 26.0 to 28.9 
weeks of gestation and 3ms for 29.0 to 32.0 weeks of gestation) (Figure 8). Figures 
9 and 10 illustrate the normal ranges for the STV240 and STV16 respectively . 
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Figure 9: Normal range 
for STV 240 in ms (5th, 
50th, 95th Percentiles)
Figure 10: Normal range 
for STV16 in ms (5th, 
50th, 95th Percentiles)
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Correlations between STV and week of pregnancy
Table 7 shows the correlations between STV240, STV16 and week of pregnancy. 
The STV240 has a relative strong, statistically significant correlation with the STV16 
(r=0,646, p<0,001). A medium, although statistically significant correlation (r=0,373, 
p<0,001) between week of pregnancy and STV240 was documented, whereas the 
correlation between STV16 and week of pregnancy was negligible [Kouskouti et al, 
2018].
Table 7: Correlations between STV240, STV16 and week of pregnancy
STV under RDS prophylaxis
An additional 57 CTG traces were registered under the influence of RDS 
prophylaxis and used for the verification of the transient effects of corticosteroids on 
the STV.
When compared to the STV240 and STV16 without RDS prophylaxis or at least 
72h after the first intramuscular corticosteroid administration, a transient increase of 
both the STV240 and STV16 was documented in the first 24h. This was followed by 
a transient decrease of both the STV240 and STV16 between 24h and 72h after 
the first intramuscular corticosteroid injection (Figure 11).
These transient changes of both the STV240 and STV16 over time are 
statistically significant (p=0,0100 and p=0,0139 respectively, Kruskal-Wallis test) 
(Table 8). 
As illustrated in Figure 11 and Table 8 these changes are more apparent in the 
case of STV240.








Figure 11: Effect of intramuscular corticosteroid administration in the context of RDS prophylaxis 
on the STV16 and STV 240 (in ms)
Table 8: Correlations between time from RDS prophylaxis and STV240 or STV16
Mean Median Range SD p-value
(Kruskal-Wallis test)
Short time variation 16
0-24h 11.076 10.81 6.85-17.25 2.964 0.0139
25-72h 9.533 8.61 4.46-4.46 4.086
>72h or none 9.112 8.65 5.08-35.09 3.157
Short time variation 240
0-24h 2.498 2.34 1.45-4.72 0.764 0.0100
25-72h 2.112 1.81 1.03-4.16 0.782
>72h or none 2.000 1.94 1.13-4.32 0.474
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DISCUSSION
The antenatal monitoring of every pregnancy, and especially of high-risk 
pregnancies, is a very important component of the responsibilities of every 
obstetrician. Often, especially when complications occur in the early preterm period, 
this monitoring can become a very challenging task for every clinician faced with 
the need to decide on the timing of delivery. 
IUGR, characterised by placental dysfunction and carrying an increased risk of 
perinatal mortality and morbidity, is one of the major complications that can occur 
during a pregnancy. Early IUGR can pose a major monitoring and treating 
challenge for every obstetrician. 
At first, fetuses with IUGR must be singled out from the greater pool of SGA 
fetuses, on the basis of a combination of biometric parameters with fetal Doppler 
values. Once the diagnosis of IUGR has been made, the focus shifts to the 
appropriate monitoring and accordingly timing of delivery. This is where CTG plays 
its role as a key tool in the day-to-day monitoring of the antenatal well-being of the 
IUGR fetus.
There are diverse criteria for the interpretation of the CTG, mainly based on the 
the optical, subjective evaluation of various components of the fetal heart rate as an 
indicator of fetal well-being. CTG is a very sensitive screening test with a high 
negative predictive value, has however a high intra-observer variability and lacks on 
reproducibility of its results. 
cCTG was developed more than two decades ago as an advanced, electronic 
and objective assessment of the fetal heart rate, in order to help overcome these 
shortcomings of traditional antenatal CTG monitoring. The first cCTG system was 
introduced in the 1980s by Dawes and Redman and is widely known as the Oxford 
system. This is implemented in the Sonicaid Fetalcare monitor and takes into 
consideration a number of numerical, computer based, parameters known as  the 
Dawes-Redman criteria.
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One of these criteria is the STV of the FHR. STV, a measure of the micro 
fluctuations of the FHR, is one of the most significant parameters, especially in the 
antenatal monitoring of IUGR fetuses. The Dawes-Redman algorithm calculates the 
STV by dividing each minute into 16 segments, each one being 3,75 seconds long 
and including 7-10 fetal heartbeats, or 6-9 pulse intervals.
Over the years, a series of important studies has demonstrated that, when 
monitoring fetuses with preterm IUGR, STV16 values under 3ms correlate 
positively with the development of metabolic acidemia and should prompt to 
delivery.
STV16 does not, however, equal the beat-to-beat variation of the FHR. 
Measurement of the pulse interval in much smaller time fractions, so that every 
heartbeat would be taken into consideration, would theoretically lead to a more 
accurate approximation of the beat-to-beat variation, with eventually significant 
advantages for the fetal antenatal monitoring.
The advancements in the area of ICT have led to the development of new 
systems for the computerised CTG. One of these is the IntelliSpace Perinatal by 
Philips Medical. The main innovation that the new system has introduced, is a new 
algorithm for the calculation of the STV of the FHR. The new algorithm aims to 
approximate the beat-to-beat variation of the FHR, through measurement of the 
pulse interval 240 times pro minute (in comparison to 16 times pro minute in the 
Dawes-Redman algorithm).
The development of a new algorithm for the calculation of any clinical parameter 
leads to the problem of lacking reference values for the named parameter. An effort 
in our department to implement the existing cut-off values of the STV16 as 
reference values for the new STV240 algorithm resulted in highly abnormal 
findings, with STV240 values significantly below the cut-off values of the STV16. 
For that reason, the STV240 could not be used for the clinical decision making, as 
the values derived from the new algorithm were significantly lower in comparison to 
the ones for STV16. 
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This observation led to the hypothesis, that the reference values for the STV240 
should be different in comparison to the existing reference values for the STV16. 
This hypothesis was not only based on clinical observation. The discrepancy noted 
between the two different algorithms is also logically sound, as it is to be expected 
that the variation between two subsequent beats will be notably lower as the 
variation between 7-10 subsequent heartbeats.
The data resulting from our single-center, non-interventional, prospective clinical 
study confirmed our hypothesis and allowed us to calculate the reference values for 
the STV240. Those reference values have been derived from a normal collective of 
our clinic and could therefore be eventually implemented in the antenatal 
monitoring of normal fetuses. However, further evaluation and validation of every 
new medical method are required and comparison of our data to data of other 
perinatal centres around the world in the future would be of great interest.
Our results are consistent with those of other study groups developing reference 
charts for the STV when measured with a different algorithm which also attempts to 
approximate the beat-to-beat variation of the FHR. In the OmniviewSisPorto 3.7 
system, for instance, the STV is calculated through the difference between adjacent 
FHR and also results in lower normal values in comparison to the STV16 [23]. 
Of paramount importance for every clinician using the new algorithm in her or his 
everyday practice, is to know that the normal values for the STV240 (not only the 
mean value but also the 95th percentile) lie beneath the, up until now, established 
cut-off for the STV16. This stresses the fact that every clinician using computerised 
CTG should be, in advance, well aware of the algorithm implemented in his CTG 
monitors. Otherwise, there is the threat of unnecessary iatrogenic premature 
deliveries, with all relevant risks. 
Furthermore, we were able to identify and confirm the effect of corticosteroids in 
the context of RDS prophylaxis on the STV of the FHR. Our results showed, in 
accordance to the existing literature, that the RDS-prophylaxis has a transient effect 
on the STV. More specifically, the intramuscular administration of corticosteroids 
leads to a transient increase of the STV in the first 24h, followed by a transient 
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decrease. The STV returns to its normal values 72h after the first intramuscular 
corticosteroid injection. These observations stress once again the fact that a 
decreased STV within the first 72h after administration of RDS prophylaxis should 
not be an indication for an early delivery.
Another interesting fact that occurred from our data is the correlation between 
STV of the FHR and week of pregnancy. It is known that in the earlier stages of 
pregnancy the variability of the FHR is lower, because of the immaturity of the fetal 
autonomous system. Our study results have demonstrated a correlation between 
the week of pregnancy and the STV240, failed however to confirm one between the 
STV16 and the week of pregnancy. It is also intriguing, that the transient changes of 
the STV under RDS prophylaxis are more apparent in the case of STV240 in 
comparison to STV16. These combined facts raise further the question, whether the 
STV240 can indeed better approximate the beat-to-beat variation and is thus more 
accurate in comparison to the STV16. This question warrants further investigation, 
as our study population was eventually to small to draw definite conclusions.
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Patienteninformation und Einwilligungserklärung für klinische Studie
Titel der Studie: Kurzzeitvariation der fetalen Herzfrequenz in intrauteriner 
Wachstumsretardierung
Prüfstelle: Abteilung für Geburtshilfe und Pränatalmedizin 
Klinik Hallerwiese
St.-Johannis-Mühlgasse 19, 90419 Nürnberg, Tel. 0911/3340-2300
Prüfleiter: Chefarzt Professor Dr. Franz Kainer
Abteilung für Geburtshilfe und Pränatalmedizin
Klinik Hallerwiese
St.-Johannis-Mühlgasse 19, 90419 Nürnberg
Tel. 0911/33 40 - 23 00
Franz.Kainer@diakonieneuendettelsau.de
Prüfärzte: Assistenzärztin Christina Kouskouti
Assistenzärztin Dr. med. Kerstin Regner
Sehr geehrte Patientin, 
wir möchten Sie fragen, ob Sie bereit sind, an der nachfolgend beschriebenen klinischen Studie 
teilzunehmen.
Klinische Studien sind notwendig, um Erkenntnisse über die Sicherheit, Eignung und 
Leistungsfähigkeit von Medizinprodukten zu gewinnen oder zu erweitern. Diese klinische Studie 
wird in der Abteilung für Geburtshilfe und Pränatalmedizin der Klinik Hallerwiese durchgeführt.
Ihre Teilnahme an dieser klinischen Studie ist freiwillig. Sie werden in diese Studie also nur dann 
einbezogen, wenn Sie dazu schriftlich Ihre Einwilligung erklären. Sofern Sie nicht an der klinischen 
Studie teilnehmen, erwachsen Ihnen daraus keine Nachteile.
Sie wurden bereits auf die geplante Studie angesprochen. Der nachfolgende Text soll Ihnen die 
Ziele und den Ablauf erläutern. Anschließend wird ein Prüfarzt das Aufklärungsgespräch mit Ihnen 
führen. Bitte zögern Sie nicht, alle Punkte anzusprechen, die Ihnen unklar sind. Sie werden danach 
ausreichend Bedenkzeit erhalten, um über Ihre Teilnahme zu entscheiden. 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1. Warum wird diese Studie durchgeführt?
Teil der Betreuung während der Schwangerschaft ist die Aufnahme der kindlichen Herztöne auf 
eine Kurve, genannt Cardiotokogram (CTG). Anhand des Musters dieser Kurve wird entschieden, 
ob es der Norm entspricht oder auffällig ist. Auffälligkeiten im CTG können ein Hinweis darauf sein, 
dass das Baby nicht mehr ausreichend versorgt ist. 
Die kindlichen Herztöne werden elektronisch ausgewertet. Bislang gab es nur ein elektronisches 
System für die CTG-Auswertung mit Normwerten.
Durch Fortschritte in der Technologie und der EDV konnte ein neues, modernes System für die 
elektronische CTG-Auswertung entwickelt werden. Dieses System kann noch feinere Messungen 
bei der Aufzeichnung der CTG-Kurven vornehmen. Die Routine-Untersuchungen in unserer Klinik 
werden standardmäßig mit diesem neuen System durchgeführt. Für dieses elektronische System 
gibt es noch keine Normwerte.  
Ziel dieser Studie ist es Normwerte für dieses neu entwickelte System zu erheben und zu 
vergleichen, ob das neue System dem alten überlegen ist, vor allem bei der Beurteilung von 
Wachstumseingeschränkten Kindern.
2. Wie ist der Ablauf der Studie?
Wie es Ihnen bereits bekannt ist, werden im Rahmen der Betreuung bei uns täglich CTGs 
geschrieben, um das Wohlbefinden des ungeborenen Kindes zu überwachen. Außerdem werden 
Ultraschall und Doppler Untersuchungen des Babys zur Bestätigung eines normalen Wachstums, 
oder um sein Wachstum zu überwachen, falls Auffälligkeiten aufgetreten sind, durchgeführt.
Für diese Studie werden die CTG-Kurven, die von Ihnen routinemäßig erhoben werden, mit 
beiden elektronischen Systemen ausgewertet, damit neue Normwerte für das neue System 
erstellt werden können, um die beiden Systemen zu vergleichen. Hierfür ist Ihre 
Zustimmung nötig.
Zusätzlich werden die Daten von Ihren Ultraschalluntersuchungen dokumentiert, um festzustellen, 
ob Ihr Baby ein normales Wachstum oder eine Wachstumseinschränkung hat. Und zum Schluss 
werden die Geburtsdaten (z.B. Gewicht, Blutwerte, APGAR) Ihres Babys dokumentiert, um die 
Genauigkeit des Systems zu kontrollieren.
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Ziel der Studie ist der Vergleich von zwei unterschiedlichen 
elektronischen Systemen für die CTG-Auswertung.
Für die Studie werden Ihre geplanten CTGs mit beiden 
elektronischen Systemen analysiert. 
3. Habe ich einen persönlichen Nutzen oder Risiken mit der Teilnahme an der Studie?
Weder einen persönlichen Nutzen, noch Risiken sind mit Teilnahme an dieser Studie verbunden. 
Es werden bei Ihnen keine zusätzlichen Untersuchungen oder Interventionen durchgeführt und 
jede klinische Entscheidung wird anhand etablierter Verfahren getroffen. 
Da es für Sie keine studienbedingten Risiken gibt, wird keine verschuldensunabhängige 
Versicherung im Rahmen der Studie abgeschlossen.
4. Was geschieht mit meinen Daten?
Ihre Daten werden in unserer Klinik, von unten genannten Mitarbeitern, aufgenommen und 
elektronisch gespeichert. Zu Ihren Originaldaten haben nur unten genannte Mitarbeiter Zugriff. 
Diese Originaldaten werden anschließend irreversibel anonymisiert und der Firma Philips Medizin 
Systeme Böblingen weitergegeben, welche die Auswertung der CTG-Kurven mit beiden 
elektronischen Systemen durchführt. Diese Auswertungen werden dann für die Ziele der Studie 
verwendet, um die Normwerte zu erstellen und die beiden Systeme zu vergleichen.
Datenschutzpassus
Bei dieser Studie werden die Vorschriften über die ärztliche Schweigepflicht und den Datenschutz 
eingehalten. Es werden persönliche Daten und Befunde über Sie erhoben, gespeichert und in 
irreversibel anonymisierter Form weitergegeben.
Der Zugang zu den Originaldaten ist auf folgende Personen beschränkt: 
Chefarzt Professor Dr. F. Kainer
Assistenzärztin C. Kouskouti
Assistenzärztin Dr. med. K. Regner
Hebamme H. Jonas
Die Unterlagen werden in der Abteilung für Geburtshilfe und Pränatalmedizin der Klinik Hallerwiese 
elektronisch und mit Passwort geschützt aufbewahrt. 
Im Falle des Widerrufs Ihrer Einwilligung werden die gespeicherten Daten vernichtet. 
Im Falle von Veröffentlichungen der Studienergebnisse bleibt die Vertraulichkeit der persönlichen 
Daten gewährleistet. 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Kurzzeitvariation der fetalen Herzfrequenz in intrauteriner Wachtumsretardierung
Einwilligungserklärung
Ich bin in einem persönlichen Gespräch durch den Prüfarzt ausführlich und verständlich über die 
klinische Studie aufgeklärt worden. Ich habe darüber hinaus den Text der Patienteninformation 
sowie die hier nachfolgend abgedruckte Datenschutzerklärung gelesen und verstanden. Ich hatte 
die Gelegenheit, mit dem Prüfarzt über die Durchführung der klinischen Studie zu sprechen. Alle 
meine Fragen wurden zufrieden stellend beantwortet.
Mir ist bekannt, dass ich jederzeit und ohne Angabe von Gründen meine Einwilligung zur 
Teilnahme an der Studie zurückziehen kann (mündlich oder schriftlich), ohne dass mir daraus 
Nachteile für meine medizinische Behandlung entstehen.
Ich erkläre mich bereit, an der oben genannten klinischen Studie freiwillig teilzunehmen. 
Ich bin mit der Erhebung und Verwendung persönlicher Daten und Befunddaten nach 
Maßgabe der Patienteninformation einverstanden.
Die Patienteninformation sowie eine Kopie der Einwilligungserklärung habe ich erhalten. 
_____________________________________ ____________________
Name der Patientin in Druckbuchstaben geb. am
_____________________________________ _____________________
Unterschrift der Patientin Ort, Datum
Ich habe das Aufklärungsgespräch geführt und die Einwilligung der Patientin eingeholt.
_____________________________________
Name des Prüfarztes/der Prüfärztin in Druckbuchstaben
_____________________________________ _____________________














Ich erkläre hiermit an Eides statt,  
  







selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und 
alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als 
solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle 
einzeln nachgewiesen habe.  
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in 
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